- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Philip Scheltens, VU University Medical Center
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
Donaghy and McKeith review the pathology of Lewy body disease and the clinical presentation of prodromal dementia with Lewy bodies (DLB), discussing how this relates to potential biomarkers of prodromal DLB.
Acetylcholinesterase inhibitor galantamine lowered the rate of whole brain atrophy, but not hippocampal atrophy, in mild cognitive impairment patients that carried the ε4 allele of apolipoprotein E only.
Cerebral inflammation, and not amyloid or tau pathology, is an independent risk factor for early death in Alzheimer’s disease (AD), which has implications for future clinical trials of disease-modifying therapies.
A meeting report from the Alzheimer’s Research UK annual conference, held in March 2014, provides an overview of current international dementia research from fundamental disease mechanisms to clinical studies.
Over the past decade, 99.6% of drugs entering the Alzheimer’s disease drug development pipeline have failed and the number of clinical trials has been declining since the 2008 to 2009 period.
A new diagnostic scale based on cerebrospinal fluid (CSF) biomarkers can help the interpretation of CSF multivariate data to identify probabilities of patients with cognitive impairments developing Alzheimer’s disease pathology.
A nationwide study of 19, 743 dementia patients in the Swedish Dementia Registry showed that cardiovascular medication is used extensively across all dementia disorders, particularly in vascular and mixed dementias.
Martinez-Ramirez and colleagues review the pathophysiology and clinical implications of cerebral microbleeds and the link with cognitive impairment and Alzheimer's disease (AD).
Latest free review
The following review has recently become free to access:
Charles Bernick, Sarah BanksAlzheimer's Research & Therapy 2013, 5:23 (4 June 2013)
News from Alzforum
From the blog
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
The evolving field of traumatic brain injury
What do we currently know about chronic traumatic encephalopathy (CTE) and what are the most important questions in the field? Listen to a free podcast discussing this and more, as part of our special series on Traumatic Brain Injury.
Searching for biomarkers
As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.